Aripiprazole Tablet
Product Images NDC 43547-306

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43547-306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare U.s., Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2f5cad93-figure-02 (2f5cad93 Figure 01)

Chemical structure of aripiprazole, the active ingredient in ARIPIPRAZOLE tablets by Solco Healthcare U.S., LLC. The diagram shows the molecular arrangement including chlorinated phenyl rings, piperazine ring, and quinolinone moiety.*

FDA Label Image

2f5cad93-figure-03 (2f5cad93 Figure 02)

A chart titled 'Effect of Other Drugs on Aripiprazole' displaying the fold change and 90% confidence interval for AUC and Cmax parameters in the presence of various interacting drugs. The chart compares changes relative to a reference without interacting drugs, listing CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lorazepam). It shows how these drugs affect aripiprazole pharmacokinetics.*

FDA Label Image

2f5cad93-figure-04 (2f5cad93 Figure 03)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals in dehydro-aripiprazole levels and AUC/Cmax relative to reference without interacting drug. The chart compares impact by CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), valproate, and lorazepam, illustrating their influence on aripiprazole metabolism.*

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\figure 4.png (2f5cad93 Figure 04)

A forest plot chart illustrating the effect of aripiprazole on the pharmacokinetics of various other drugs. The chart displays fold change and 90% confidence intervals for pharmacokinetic parameters such as AUC, Cmax, and INR for drugs including dextromethorphan, warfarin (S- and R- forms), omeprazole, lamotrigine, valproate, lorazepam, venlafaxine, and O-desmethylvenlafaxine, showing changes relative to a reference without interacting drug.*

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\figure 5.png (2f5cad93 Figure 05)

A chart titled "Aripiprazole Fold Change and 90% CI" showing pharmacokinetic changes (AUC and Cmax) relative to reference in special populations: CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The horizontal axis represents change relative to reference from 0.5 to 3.0, with data points and 90% confidence intervals displayed for each category.*

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\figure 6.png (2f5cad93 Figure 06)

A pharmacokinetic plot showing the fold change and 90% confidence intervals in dehydro-aripiprazole levels relative to a reference. The chart compares variables including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, illustrating their effects on AUC and Cmax values.*

FDA Label Image

2f5cad93-figure-08 (2f5cad93 Figure 07)

A line chart comparing the proportion of subjects with relapse over time between aripiprazole and placebo groups. The x-axis shows days, and the y-axis indicates the proportion with relapse. The chart includes a risk table displaying the number of subjects at risk at various time points for both groups, with aripiprazole represented by a solid blue line and placebo by a dashed red line.*

FDA Label Image

2f5cad93-figure-09 (2f5cad93 Figure 08)

A Kaplan-Meier curve showing the proportion of subjects with relapse over days from randomization comparing aripiprazole and placebo. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse ranging from 0 to 1. The graph includes a risk table displaying the number of subjects at risk for each group (aripiprazole and placebo) at various time points.*

FDA Label Image

C:\users\ra\desktop\3.jpg (Arpiprazole 10mg 100count)

Aripiprazole Tablets USP 10 mg oral tablets label shows 100 tablets per container. Label includes storage instructions, manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd., and distributor Solco Healthcare US, LLC. The label features a blue and yellow design with directions to dispense the enclosed medication guide.*

FDA Label Image

C:\users\ra\desktop\4.jpg (Arpiprazole 15mg 100count)

Label for Aripiprazole Tablets USP, 15 mg, oral tablets manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd., distributed by Solco Healthcare US, LLC. The label includes storage instructions, distributor information, a barcode, and a note to dispense the enclosed Medication Guide. The package contains 100 tablets.*

FDA Label Image

C:\users\ra\desktop\5.jpg (Arpiprazole 20mg 100count)

Aripiprazole Tablets USP 20 mg label from Solco Healthcare U.S., LLC. The label indicates prescription use only and includes directions for pharmacists to dispense the enclosed Medication Guide. It states packaging contains 100 tablets. Storage instructions and manufacturer details from Zhejiang Huahai Pharmaceutical Co., Ltd. are also included. The NDC code is 43547-306-10.*

FDA Label Image

C:\users\ra\desktop\1.jpg (Arpiprazole 2mg 100count)

Label for Aripiprazole Tablets USP, 2 mg, manufactured by Zhejiang Huahai Pharmaceutical Co. and distributed by Solco Healthcare US, LLC. The label indicates the product contains 100 tablets and instructs pharmacists to dispense an enclosed Medication Guide. Storage instructions specify keeping the tablets between 20° to 25°C with allowable excursions.*

FDA Label Image

C:\users\ra\desktop\6.jpg (Arpiprazole 30mg 100count)

Aripiprazole Tablets USP 30 mg oral tablets by Solco Healthcare U.S., LLC. The label indicates 100 tablets per container with prescription only status. It includes storage instructions, manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd., and distributor information. The label features a blue and yellow design with dosage and tablet count prominently displayed.*

FDA Label Image

C:\users\ra\desktop\2.jpg (Arpiprazole 5mg 100count)

Label for Aripiprazole tablets, USP, 5 mg strength, manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. and distributed by Solco Healthcare U.S., LLC. The label indicates packaging of 100 tablets, with storage directions and a note for pharmacists to dispense the Medication Guide with each patient. The label includes a barcode and NDC 43547-303-10.*

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\structure.jpg (Structure)

Chemical structure of aripiprazole, the active ingredient in ARIPIPRAZOLE tablets. The diagram shows the molecular arrangement including aromatic rings, chloride atoms, and nitrogen-containing groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.